Loading
companiesCompany
Revolution Medicines
Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.
Also called: EQRx International, Inc.EQRx
Overview
Revolution Medicines, based in Redwood City, California, and listed as RVMD, is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer. Its pipeline pairs daraxonrasib, a pan-RAS inhibitor, with elironrasib, selective for G12C in the active state, and zoldonrasib against G12D, tested in the RASolute and RASolve phase 3 programmes, and the company expanded its credit facility in 2025 to fund a launch. OnCo links it to pancreatic ductal adenocarcinoma, to the KRAS roadmap from undruggable through G12C to pan-RAS, to the bottleneck of undruggable drivers, and to the idea of covalent chemistry for RAS mutations that still have no drug. Whether pan-RAS inhibition is tolerable enough for long-term use is the open question. Daraxonrasib has its own page.
Headquarters
Redwood City, CA, US
Scorecard
All companies#213of 1244 companies, score 25
- approved products +6
- phase 1/2 +2
- targets +2
- modalities +2
- regions +1
- 24-month regulatory events +4
- registry trials +8
1 approved, 0 in phase 3, 2 earlier, 1 targets, 16 registry studies. Formula on the scorecards page.
Financial snapshot, FY2024
- R&D spend
- $0.7bn
- Cash
- $2.3bn
Pre-commercial; cash includes marketable securities. Revolution Medicines Form 10-K, FY2024 (SEC EDGAR)
Type
Biotech · RVMD
Stage
Public
Website
ApprovedSmall-molecule pan-RAS(ON) inhibitor
Daraxonrasib · Rasonque
The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.
Phase 2Small-molecule RAS(ON) G12C-selective inhibitor
A next-generation KRAS G12C drug that hits the active form of the protein, from the same company as daraxonrasib.
Phase 2Small-molecule RAS(ON) G12D-selective inhibitor
The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding.
Similar pages
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC), Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta, Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma, RASolute 302.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares Zoldonrasib, RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors, Zoldonrasib, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
- Key paperDaraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Shares Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy, RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS, Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut, Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression.
- TrialCodeBreaK 100 (pancreatic cancer cohort)
Shares RASolute 302, Daraxonrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
- CompanyQuanta Therapeutics
Shares Covalent chemistry for the RAS mutations that still have no drug, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares KRAS roadmap: undruggable → G12C → pan-RAS, Daraxonrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
cancers
fronts
technologies
drugs
ApprovedSmall-molecule pan-RAS(ON) inhibitor
Daraxonrasib · Rasonque
Phase 2Small-molecule RAS(ON) G12C-selective inhibitor
Phase 2Small-molecule RAS(ON) G12D-selective inhibitor
companies
trials
RASolute 302Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsStudy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-MuStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-MutStudy of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta